Sentences with phrase «global product programs»

This week's guest of honor is Ford's Barb Samardzich, the Vice President of Global Product Programs.

Carlisle's replacement in this game of executive musical chairs is Australian Travis Hester, currently the VP of Global Product Programs.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

About Marriott Vacations Worldwide Corporation Marriott Vacations Worldwide Corporation is a leading global pure - play vacation ownership company, offering a diverse portfolio of quality products, programs and management expertise with over 65 resorts.

A team under Airbnb's global head of social impact, Kim Rubey, was already working on a program to house refugee relief workers in Greece, Macedonia and Serbia, but to address the product challenge, Gebbia formed a new team under his Samara studio that was ultimately spun out and called the Human team.

Segmented products and loyalty programs were also factors helping global brands continue attracting business travelers, the report stated.

When customers buy (PRODUCT) RED products, Apple donates a portion of the proceeds to the Global Fund HIV / AIDS grants that provide a range of programs to eradicate AIDS or help people who have been affected by AIDS.

CNBC has a vast portfolio of digital products across a variety of platforms including: CNBC.com; CNBC PRO, the premium, integrated desktop / mobile service that provides live access to CNBC programming, exclusive video content and global market data and analysis; a suite of CNBC mobile products including the CNBC Apps for iOS, Android and Windows devices; and additional products such as the CNBC App for the Apple Watch and Apple TV.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

These include CNBC.com, the online destination for global business; CNBC PRO, the premium, integrated desktop / mobile service that provides real - time global market data and live access to CNBC global programming; and a suite of CNBC Mobile products including the CNBC Real - Time iPhone and iPad Apps.

Those who have left Uber in recent times have included the VP of maps and business platform Brian McClendon, president Jeff Jones, AI lead Gary Marcus, communications SVP Rachel Whetstone, VP of global vehicle programs Sherif Marakby, VP of product Ed Baker, SVP of engineering Amit Singhal and self - driving car head Anthony Levandowski.

About Marriott Vacations Worldwide Corporation Marriott Vacations Worldwide Corporation is the leading global pure - play vacation ownership company offering a diverse portfolio of quality products, programs and management expertise with more than 60 resorts and more than 420,000 Owners and Members.

About Marriott Vacations Worldwide Corporation Marriott Vacations Worldwide Corporation is a leading global pure - play vacation ownership company, offering a diverse portfolio of quality products, programs and management expertise with 62 resorts.

Marriott Vacations Worldwide Corporation is a leading global pure - play vacation ownership company, offering a diverse portfolio of quality products, programs and management expertise with over 65 resorts.

The phenomenon is the result of several converging forces: pressure from activist shareholders; executive compensation programs that tie pay to per - share earnings and share prices that buybacks can boost; increased global competition; and fear of making long - term bets on products and services that may not pay off.

About Marriott Vacations Worldwide Corporation Marriott Vacations Worldwide Corporation is a leading global pure - play vacation ownership company offering a diverse portfolio of quality products, programs and management expertise with more than 60 resorts and more than 420,000 Owners and Members.

Now, in addition to expanding product offerings, Tmall Global wants to enhance the platforms «stickiness» by building membership programs for consumers in partnership with merchants, as well as an online community where mothers can share their knowledge and experiences.

Examples mentioned included the company's programs for spotting and taking down counterfeit - product listings from its online shopping sites, initiatives to simplify the trademark - registration process, reductions in the time it takes to remove counterfeit products, closer partnerships with global law enforcement authorities and governments, and the imposition of a variety of penalties against offending merchants, among others.

About Marriott Vacations Worldwide Corporation Marriott Vacations Worldwide Corporation is a leading global pure - play vacation ownership company, offering a diverse portfolio of quality products, programs and management expertise.

The BRC Global Standard is a leading product safety and quality certification program used by manufacturers in over 100 countries.

DuPont Packaging & Industrial Polymers leverages its science and technology know - how through a global development team working with converters, brand owners, retailers and others on packaging programs in the areas of total cost reduction, product protection, environmental stewardship, shelf appeal and convenience.

And Jason Clay, Senior Vice President, Markets and Food at WWF added, «This shift offers an opportunity to help marginal producers in developing countries realize higher returns for their products through the simplification of global certification programs.

The program provides opportunities for U.S. producers of all sizes to connect with qualified global buyers — online and in - person — who are seeking to meet their customers» growing demand for USDA organic products.

The 2014 program schedule included: culinary demonstrations centered around adventurous flavors and new menu trends; presentations and panel discussions focused on sustainable agricultural practices, the role of wheat in our diet vs. seekers of gluten - free options, and water issues affecting food production; discussions on how American menus are often shaped by millennials, health and nutrition concerns, and global cuisines; a Friday field trip to the CIA Farm in St. Helena and through Marin and Sonoma Counties to visit Pozzi Ranch, Dutton Ranch (where Valley Ford Cheese Company joined), and Gourmet Mushrooms with tastings and presentations by the farmers as well as farm bureau and land trust experts; and the exciting and interactive Saturday Market Basket Exercise, where attendees were divided into six teams to develop menu concepts using sponsor products for the following categories:

The Global Animal Partnership Program will give insights into how its animal welfare rating scheme is educating consumers on sustainable meat products.

As with all Fork in the Road products, the sausages are produced from meat raised without the use of antibiotics and added hormones, and is animal welfare certified under the Global Animal Partnership (GAP) 5 - Step Program.

The Gluten Intolerance Group (GIG), the leader in the certification of gluten - free products and food services, announced that it has partnered with SGS, a global inspection, verification, testing and certification company, to be the first certification body approved to audit in conjunction with GIG's Gluten - Free Certification Organization (GFCO) program standards.

SCOTTSDALE, Ariz., May 5, 2016 / PRNewswire / — RiceBran Technologies (NASDAQ: RIBT and RIBTW)(the «Company» or «RBT»), a global leader in the production and marketing of value added products derived from rice bran, announced today that it has entered into two agreements: a Memorandum of Understanding (MOU) with non-profit The Jack Brewer Foundation (JBF Worldwide) to develop rice bran based supplemental feeding programs currently assisted by JBF Worldwide at orphanages in Malawi and Haiti; and a business development agreement with Brewer + Associates Consulting, LLC (B+A) to collaborate on the planned launch of a new line of sports nutrition products with a portion of profits earmarked to provide rice bran based meal supplements for feeding programs covered by the MOU.

In 2015, we migrated to a Global Food Safety Initiative (GFSI) based program in an effort to ensure the very highest attention to the safety and security of the products we provide.

«This shift offers an opportunity to help marginal producers in developing countries realize higher returns for their products through the harmonization and simplification of global certification programs.

The Winter Fancy Food Show Trendspotter Panel included Polly Adema, PhD, associate professor and director of graduate Food Studies Program, University of the Pacific SF; Kara Nielsen, vice president, Trends & Marketing, CCD Innovation; Tu David Phu, chef / owner, AN — a Vietnamese Dining Experience; and Joey Wells, American Cheese Society Certified Cheese Professional and Whole Foods Market Global Senior Coordinator overseeing Specialty Cheese Product Innovation & Development.

«Virtuoso has been hand - selecting the world's finest properties for its famed Hotels & Resorts program for more than two decades, so deciding which ones represent the Best of the Best is challenging each year,» said Albert Herrera, senior vice president, Global Product Partnerships for Virtuoso.

The program demands global collaboration among researchers in academia and industry, facilitates partnered clinical development by disparate biopharma companies, utilizes a one - of - a-kind clinical infrastructure that took over a decade to assemble, and invests in research - driven (as opposed to product - driven) clinical trials.

It combines Global Healing Center's best gut health products into one incredibly effective program that will cleanse your gut, balance your microbiota, and lay the foundation for abdominal comfort and peace.

Through the Global Healing Center Affiliate Program you can earn commissions on more than 60 high - quality products including dietary supplements, organic skin care products, complete cleansing systems, and ebooks about maximizing health.

Paramount Pictures Corporation (PPC), a major global producer and distributor of filmed entertainment, is a unit of Viacom (NASDAQ: VIAB, VIA), home to premier global media brands that create compelling television programs, motion pictures, short - form content, apps, games, consumer products, social media experiences, and other entertainment content for audiences in more than 180 countries.

Alexandria, VA (6/16/2011)-- ASCD, the global leader in providing programs, products, and services that empower educators to support the success of each learner, invites teachers and education leaders from around the globe to attend the Differentiated Instruction Institutes on August 18 — 19, 2011, in Vancouver, British Columbia.

Alexandria, VA (05/17/12)-- ASCD, the global leader in developing and delivering innovative programs, products, and services that empower educators to support the success of each learner, has compiled a summer reading list for administrators, teacher leaders, and classroom educators interested in low - cost, high - impact professional development.

Product related educational material is transformed into online multi-lingual eLearning programs for global workforce in their native languages.

Alexandria, VA (1/5/2012)-- ASCD, the global leader in providing programs, products, and services that empower educators to support the success of each learner, announces the release of seven new PD Online ® courses for educators integrating Common Core State Standards into classroom instruction.

Alexandria, VA (05/22/2012)-- ASCD, the global leader in providing programs, products, and services that empower educators to support the success of each learner, announces the release of seven new PD Online ® courses for educators focused on differentiated instruction, Common Core State Standards implementation, and teaching students in high - poverty communities.

Alexandria, VA (07/12/2012)-- ASCD, the global leader in developing and delivering innovative programs, products, and services that empower educators to support the success of each learner, is bringing its Fall Conference on Revolutionizing the Way We Lead and Learn to Atlanta, Ga., October 26 — 28, 2012.

Alexandria, VA (07/17/13)-- ASCD, the global leader in providing programs, products, and services that empower educators to support the success of each learner, is offering two new webinars on the Common Core State Standards this summer at no cost.

Alexandria, VA (09/14/11)-- ASCD, the global leader in providing programs, products, and services that empower educators to support the success of each learner, announces the addition of Efrain Mercado Jr. and Katie Hill to its public policy team.

Alexandria, VA (03/06/2012)-- ASCD, the global leader in providing programs, products, and services that empower educators to support the success of each learner, introduces two new institute series and free webinars to help educators nationwide implement the new Common Core State Standards.

ASCD is the global leader in providing programs, products, and services that empower educators to support the success of each learner.

Alexandria, VA (6/23/11)-- As educators across the nation wipe their chalkboards clean and close up school for summer, ASCD, the global leader in providing programs, products, and services that empower educators to support the success of each learner, offers four ways to stay sharp over the break.

Alexandria, VA (08/16/2012)-- ASCD, the global leader in developing and delivering innovative programs, products, and services that empower educators to support the success of each learner, has unveiled the free, online ASCD School Improvement Tool, which is based on a whole child approach to education.

Alexandria, VA (06/14/12)-- ASCD, the global leader in providing programs, products, and services that empower educators to support the success of each learner, announces the 2012 Summer Boot Camp webinar series.

Alexandria, VA (10/09/2012)-- ASCD, the global leader in providing programs, products, and services that empower educators to support the success of each learner, announces the release of three new PD Online ® courses focused on Common Core State Standards and differentiated instruction.